X-Nico

3 unusual facts about Tissue Plasminogen Activator


David Goeddel

David Goeddel (born 1951 in San Diego) is a pioneer of the biotechnology industry who, employed at the time by Genentech, successfully used genetic engineering to coax bacteria into creating synthetic human insulin, human growth hormone, and human Tissue plasminogen activator (tPA) for use in therapeutic medicine.

Memorial Hermann–Texas Medical Center

Dr. James Grotta was principal investigator in Houston for the first major trial showing benefits of clot-busting drug Tissue Plasminogen Activator (tPA).

RTPA

rtPA may refer to Recombinant tissue plasminogen activator, a protein involved in the breakdown of blood clots.



see also